Liquidia Corporation

We are deeply passionate and committed to the discovery, engineering, and development required to bring novel therapies to patients who need them most, and to the healthcare providers who care for them. Our current drive is toward improving the treatment of pulmonary arterial hypertension (PAH).

We will continue to combine our proprietary, innovative PRINT Technology with new and established medications, offering the potential for both better precision and improved clinical outcomes.

News Releases

NOV 11 2021

Liquidia to Participate in the Jefferies London Healthcare Conference

MORRISVILLE, N.C. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta , Chief Financial Officer of Liquidia , will provide an update on the company's business during a fireside chat at the Jefferies 2021 Virtual London Healthcare
NOV 08 2021

FDA Grants Tentative Approval for Liquidia’s YUTREPIA™ (Treprostinil) Inhalation Powder

First dry-powder formulation of treprostinil to meet criteria required for FDA approval Final FDA approval may occur in October 2022 or earlier upon resolution of on-going litigation Conference call and webcast scheduled for today at 9:00 a.m. Eastern Standard Time MORRISVILLE, N.C. , Nov.

btn News